晚期甲状腺髓样癌的治疗
Treatment of advanced medullary thyroid cancer.
作者信息
Smit Johannes
机构信息
Department of General Internal Medicine, Radboud University Nijmegen Medical Centre P,O, Box 9101, 6500 HB Nijmegen, The Netherlands.
出版信息
Thyroid Res. 2013 Mar 14;6 Suppl 1(Suppl 1):S7. doi: 10.1186/1756-6614-6-S1-S7.
Abstract
Therapy decisions in advanced medullary thyroid carcinoma should be guided by a critical appraisal of the natural disease course (slowly progressive vs. aggressive) and benefits and side effects of therapy. Therapy goals should be distinguished between curative and palliative. Local treatments are mainly palliative and may add to quality of life. The advent of novel systemic therapies opens promising perspectives but its place in the therapeutic arsenal must be further determined.
摘要
晚期甲状腺髓样癌的治疗决策应以对疾病自然病程（缓慢进展型与侵袭型）以及治疗的获益和副作用进行批判性评估为指导。治疗目标应区分根治性和姑息性。局部治疗主要是姑息性的，可能会提高生活质量。新型全身治疗方法的出现带来了有前景的治疗前景，但它在治疗手段中的地位仍需进一步确定。
相似文献
1
Treatment of advanced medullary thyroid cancer.晚期甲状腺髓样癌的治疗
Thyroid Res. 2013 Mar 14;6 Suppl 1(Suppl 1):S7. doi: 10.1186/1756-6614-6-S1-S7.
2
[Systemic treatment of metastasized thyroid cancer-approved treatments and new approaches].[转移性甲状腺癌的系统治疗——批准的治疗方法和新途径]
Chirurg. 2020 Dec;91(12):1038-1043. doi: 10.1007/s00104-020-01284-7.
3
Prognostic and predictive markers in medullary thyroid carcinoma.甲状腺髓样癌的预后和预测标志物。
Endocr Pathol. 2012 Dec;23(4):232-42. doi: 10.1007/s12022-012-9225-8.
4
Management of invasive and advanced thyroid cancer.侵袭性和晚期甲状腺癌的管理
Minerva Endocrinol. 2009 Mar;34(1):37-55.
5
Alternative therapeutic approaches in the treatment of primary and secondary dedifferentiated and medullary thyroid carcinoma.分化型和髓样甲状腺癌原发和继发去分化治疗的替代治疗方法。
Semin Nucl Med. 2011 Mar;41(2):139-48. doi: 10.1053/j.semnuclmed.2010.10.005.
6
Locally advanced thyroid cancer: therapeutic options.局部晚期甲状腺癌：治疗选择
Chir Ital. 2004 Jul-Aug;56(4):501-8.
7
Treatment of advanced thyroid cancer with targeted therapies: ten years of experience.靶向治疗晚期甲状腺癌：十年经验
Endocr Relat Cancer. 2016 Apr;23(4):R185-205. doi: 10.1530/ERC-15-0555.
8
Aggressive Palliation and Survival in Anaplastic Thyroid Carcinoma.间变性甲状腺癌的积极姑息治疗与生存情况
JAMA Otolaryngol Head Neck Surg. 2015 Dec;141(12):1128-32. doi: 10.1001/jamaoto.2015.2332.
9
[Progression of diagnosis and treatment of medullary thyroid carcinoma].[甲状腺髓样癌的诊断与治疗进展]
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2019 Apr 7;54(4):306-310. doi: 10.3760/cma.j.issn.1673-0860.2019.04.015.
10
Long-Term Follow-up in Medullary Thyroid Carcinoma.甲状腺髓样癌的长期随访
Recent Results Cancer Res. 2015;204:207-25. doi: 10.1007/978-3-319-22542-5_10.
引用本文的文献
1
A Rare Case of Thyroid Metastasis Secondary to Hidden Undiagnosed Lung Adenocarcinoma.隐匿性未诊断肺腺癌继发甲状腺转移1例罕见病例
J Med Cases. 2020 Oct;11(10):336-338. doi: 10.14740/jmc3557. Epub 2020 Aug 28.
2
Not all that is miliary is tuberculosis: Metastatic medullary thyroid carcinoma mimicking miliary tuberculosis.并非所有粟粒状病变都是结核病：转移性甲状腺髓样癌酷似粟粒性结核。
Clin Case Rep. 2021 May 15;9(5):e04231. doi: 10.1002/ccr3.4231. eCollection 2021 May.
3
The Impact of Transcription Factor Prospero Homeobox 1 on the Regulation of Thyroid Cancer Malignancy.转录因子 Prospero 同源盒 1 对甲状腺癌恶性肿瘤的调控作用。
Int J Mol Sci. 2020 May 2;21(9):3220. doi: 10.3390/ijms21093220.
4
The added diagnostic value of complementary gadoxetic acid-enhanced MRI to F-DOPA-PET/CT for liver staging in medullary thyroid carcinoma.钆塞酸增强 MRI 对 F-DOPA-PET/CT 用于甲状腺髓样癌肝脏分期的附加诊断价值。
Cancer Imaging. 2019 Nov 14;19(1):73. doi: 10.1186/s40644-019-0263-z.
5
Prognostic significance and optimal cutoff of age in medullary thyroid cancer.甲状腺髓样癌中年龄的预后意义及最佳临界值
Oncotarget. 2016 Mar 29;7(13):15937-47. doi: 10.18632/oncotarget.7556.
6
Recurrent spinal metastasis of a sporadic medullary carcinoma of the thyroid after radiation therapy: a case report and review of the literature.甲状腺散发性髓样癌放疗后复发性脊柱转移：一例报告并文献复习
Clin Case Rep. 2015 Nov 9;4(1):9-18. doi: 10.1002/ccr3.409. eCollection 2016 Jan.
7
Introduction to European comments on "Medullary Thyroid Cancer: management guidelines of the American Thyroid Association".欧洲对《甲状腺髓样癌：美国甲状腺协会管理指南》的评论介绍
Thyroid Res. 2013 Mar 14;6 Suppl 1(Suppl 1):S1. doi: 10.1186/1756-6614-6-S1-S1.
本文引用的文献
1
Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.凡德他尼治疗局部晚期或转移性甲状腺髓样癌患者的疗效：一项随机、双盲 III 期临床试验。
J Clin Oncol. 2012 Jan 10;30(2):134-41. doi: 10.1200/JCO.2011.35.5040. Epub 2011 Oct 24.
2
Multikinase inhibitors: a new option for the treatment of thyroid cancer.多激酶抑制剂：甲状腺癌治疗的新选择。
Nat Rev Endocrinol. 2011 Aug 23;7(10):617-24. doi: 10.1038/nrendo.2011.141.
3
New treatment modalities in advanced thyroid cancer.晚期甲状腺癌的新治疗方法。
Ann Oncol. 2012 Jan;23(1):10-18. doi: 10.1093/annonc/mdr117. Epub 2011 Apr 6.
4
Pretargeted radioimmunotherapy in the treatment of metastatic medullary thyroid cancer.预靶向放射免疫疗法治疗转移性甲状腺髓样癌
Curr Oncol. 2009 Sep;16(5):3-8. doi: 10.3747/co.v16i5.464.
5
Medullary thyroid cancer: management guidelines of the American Thyroid Association.甲状腺髓样癌：美国甲状腺协会管理指南
Thyroid. 2009 Jun;19(6):565-612. doi: 10.1089/thy.2008.0403.
6
Radiofrequency ablation of hepatic metastases from thyroid carcinoma.甲状腺癌肝转移灶的射频消融治疗
Thyroid. 2008 Oct;18(10):1105-10. doi: 10.1089/thy.2008.0080.
7
Airway stenting for the treatment of laryngotracheal stenosis secondary to thyroid cancer.气道支架置入术治疗甲状腺癌继发的喉气管狭窄。
Respirology. 2008 Sep;13(5):632-8. doi: 10.1111/j.1440-1843.2008.01309.x. Epub 2008 May 29.
8
18F-dihydroxyphenylalanine PET in patients with biochemical evidence of medullary thyroid cancer: relation to tumor differentiation.18F-二羟基苯丙氨酸PET在甲状腺髓样癌生化证据患者中的应用：与肿瘤分化的关系
J Nucl Med. 2008 Apr;49(4):524-31. doi: 10.2967/jnumed.107.047720.
9
Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times.甲状腺髓样癌的进展：降钙素和癌胚抗原倍增时间的评估
Eur J Endocrinol. 2008 Feb;158(2):239-46. doi: 10.1530/EJE-07-0667.
10
Long-term outcome of reoperations for medullary thyroid carcinoma.甲状腺髓样癌再次手术的长期预后
World J Surg. 2008 May;32(5):754-65. doi: 10.1007/s00268-007-9317-7.
Zotero 插件